112434-18-1

Basic information

• Product Name: benzyl 2,4-difluorophenylcarbaMate
• Synonyms: benzyl 2,4-difluorophenylcarbaMate;(2,4-Difluorophenyl)carbamic acid benzyl ester
• CAS NO: 112434-18-1
• Molecular Formula: C₁₄H₁₁F₂NO₂
• Molecular Weight: 263
• Mol File: 112434-18-1.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 312.1±42.0 °C(Predicted)
• Appearance: /
• Density: 1.329±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 11.69±0.70(Predicted)
• CAS DataBase Reference: benzyl 2,4-difluorophenylcarbaMate(CAS DataBase Reference)
• NIST Chemistry Reference: benzyl 2,4-difluorophenylcarbaMate(112434-18-1)
• EPA Substance Registry System: benzyl 2,4-difluorophenylcarbaMate(112434-18-1)

Safety Data

• Hazardous Substances Data: 112434-18-1(Hazardous Substances Data)

Usage

General Description

Benzyl 2,4-difluorophenylcarbamate is a chemical compound that is used in the production of various pharmaceuticals and agrochemicals. It is a carbamate derivative, which means it contains a carbamate functional group. This chemical has a benzyl group attached to the carbamate nitrogen, as well as two fluorine atoms attached to the phenyl ring at the 2 and 4 positions. Benzyl 2,4-difluorophenylcarbamate is used as an intermediate in the synthesis of several organic compounds, and it has potential applications in the development of new drugs and pesticides. Its precise role and function depend on the specific application and context in which it is used.

Upstream product

• 367-25-9 2,4-difluorophenylamine 
• 501-53-1 benzyl chloroformate 

Downstream Products

• 918509-12-3 (3-Amino-2,6-difluoro-phenyl)-(5-chloro-1H-pyrrolo[2, 3-b]pyridin-3-yl)-methanone 
• 1380229-22-0 N-(2,4-difluoro-3-(3-(9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl)pyridin-2-ylamino)phenyl)-1-methyl-1H-pyrazole-4-sulfonamide 
• 1380229-09-3 N-(2,4-difluoro-3-(3-(9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl)pyridin-2-ylamino)phenyl)pyridin-3-sulfonamide 

Relevant articles and documents

Aqueous phase mono-protection of amines and amino acids as N-benzyloxycarbonyl derivatives in the presence of β-cyclodextrin

A simple and selective protection of amines/amino acids with Cbz-Cl has been achieved in aqueous phase with catalytic amounts of β-cyclodextrin in high yields at room temperature. This reaction proceeds without the formation of any by-products and has advantages over existing methods.

COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR

Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on at least one Raf protein kinase. In certain aspects and embodiments, the described compounds are active in inhibiting proliferation of a Ras mutant cell line. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of B-Raf V600E mutant protein kinase, including melanoma, glioma, glioblastoma multiforme, pilocytic astrocytoma, colorectal cancer, thyroid cancer, lung cancer, ovarian cancer, prostate cancer, liver cancer, gallbladder cancer, gastrointestinal stromal tumors, biliary tract cancer, and cholangiocarcinoma. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of c-Raf-1 protein kinase, including acute pain, chronic pain or polycystic kidney disease.

PYRROLO [2, 3-B] PYRIDINE DERIVATIVES FOR THE INHIBITION OF RAF KINASES

Propane-1-sulfonic acid {2,4-difluoro-3-[5-(2-methoxy-pyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-phenyl}-amide, propane-1-sulfonic acid [3-(5-cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-amide, propane-1-sulfonic acid [3-(5-cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2-fluoro-phenyl]-amide, N-[3-(5-cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-2,5-difluoro-benzenesulfonamide, N-[3-(5-cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-3-fluoro-benzenesulfonamide, pyrrolidine-1-sulfonic acid [3-(5-cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-amide, N,N-dimethylamino-sulfonic acid [3-(5-cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-amide, and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, and forms thereof are active on at least one Raf protein kinase. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of Raf protein kinases, including melanoma, glioma, colorectal cancer, thyroid cancer, lung cancer, ovarian cancer, prostate cancer, and biliary tract cancer.